Lowe's, Tenneco, Tupperware, and other stocks are experiencing significant premarket movements.

Check out the companies making headlines before the bell:

Lowe's shares gained 1.6% in the premarket after the home improvement retailer surpassed both top and bottom-line estimates for the fourth quarter. Lowe's reported earnings of $1.78 per share, 7 cents above expectations, and provided optimistic full-year guidance as demand for tools and building materials remained strong.

Tenneco, an automotive components manufacturer, has agreed to be acquired by affiliates of APO for $20 per share in cash, which is a significant increase from its Tuesday closing price of $9.98 per share. The deal is expected to close in the second half of this year, and Tenneco's stock price soared 91.7% in premarket action.

Despite seeing its shares drop 3% in the premarket, Tupperware reported revenue that exceeded Street forecasts. However, its adjusted profit of 38 cents per share fell short of estimates by 14 cents due to "challenging operating conditions." Despite these challenges, Tupperware experienced growth in both its top and bottom lines in 2021.

Palo Alto Networks (PANW) exceeded earnings estimates by 9 cents in the latest quarter, with adjusted earnings of $1.74 per share and revenue that surpassed analyst predictions. Additionally, the company provided a better-than-expected forecast, causing its shares to rise 7.8% in premarket trading.

The space tourism company's stock price increased by 4.1% before the market opened, following the release of its quarterly report that showed a smaller loss than anticipated and an improvement in its cash reserves.

The merger of Fiat Chrysler and Peugeot parent PSA Group resulted in the automaker exceeding its profit targets in the first year. Additionally, the company announced that it was realizing benefits from the combination earlier than anticipated. As a result, its stock price increased by 6.3% in the premarket.

The two companies, GlaxoSmithKline and Sanofi, experienced a rise in their stock prices of 1.7% and 1.5%, respectively, after announcing that they would submit their Covid-19 vaccine for approval from global drug regulators.

The casino operator's stock increased by 4.5% during premarket trading following the release of the company's financial report, which showed a 63% increase in revenue from the previous year and a smaller loss.

The fertilizer producer's shares dropped 5.6% in premarket trading after the company's quarterly earnings and revenue did not meet analyst expectations. Mosaic stated that it anticipates upward pricing momentum to persist.

UBS downgraded the medical lab operator's stock from "buy" to "neutral," citing the risk of not meeting management's earnings target for fiscal 2023 due to the company's high level of investment in growth.

The experimental eye drug from the drugmaker did not prove to be non-inferior to Eylea in a mid-to-late stage trial for macular degeneration treatment. Kodiak's stock price dropped 69.2% in premarket trading, while Regeneron's stock price increased by 4.5%.